Tag: share

New York, June 06, 2025 (GLOBE NEWSWIRE) -- During the 2025 Monaco Grand Prix, EKOUAER made its debut As the Exclusive VIP Gifting Partner on Titania yacht, marking a key moment in the brand’s transition from a beloved loungewear label to a name now associated with elevated, modern luxury. Widely recognized as one of the most prestigious events in global motorsport, the Monaco Grand Prix attracts a rare mix of athletes, celebrities, media, and top-tier brands, making it an ideal platform for EKOUAER to share its vision. At the heart of the brand is a belief that comfort and elegance should coexist—whether at home or on the world’s most exclusive stages.Each is invited to experience EKOUAER’s signature blend of softness, simplicity, and style in an unforgettable setting.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bitfarms Ltd. ("Bitfarms" or the "Company") (NASDAQ: BITF) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-02630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bitfarms securities between March 21, 2023 and December 9, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –

DEERFIELD, Ill, June 06, 2025 (GLOBE NEWSWIRE) -- BAB, Inc. (OTCQB: BABB), today announced that its Board of Directors has declared a quarterly distribution of one cent ($0.01) per share, payable on July 14, 2025 to shareholders of record as of June 26, 2025.

Receives Notice of Failure to File Interim Financial Statements in Violation of Nasdaq Listing Rules

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.